SCHEDULE 13G/A: MAIA Biotechnology Insider Sergei Gryaznov Reports 4.08% Beneficial Ownership Stake

Sergei M. Gryaznov, an insider at MAIA BIOTECHNOLOGY, INC., has filed an amended Schedule 13G reporting a beneficial ownership of 4.08% of the company's common stock as of December 31, 2023.

Summary

• Sergei M. Gryaznov beneficially owns 1,140,115 shares of MAIA BIOTECHNOLOGY, INC. common stock.
• This ownership represents 4.08% of the company's total common stock outstanding.
• The total shares include 44,511 shares of common stock directly held and 1,095,604 shares of common stock issuable upon the exercise of stock options.
• Mr. Gryaznov holds sole voting and sole dispositive power over all 1,140,115 shares.
• The percentage is calculated based on 26,824,681 shares outstanding as of February 13, 2025, plus the 1,095,604 exercisable options.

Sentiment

Score: 5

Explanation: The document is a factual report of beneficial ownership and does not contain information that would significantly alter a positive or negative sentiment towards the company. It is neutral in tone and content.

Positives

• The significant beneficial ownership by an insider, Sergei M. Gryaznov, including a large portion from stock options, indicates strong alignment of management's interests with shareholder value.
• The substantial number of shares issuable from stock options (1,095,604 shares) suggests a long-term commitment and potential future investment in the company by Mr. Gryaznov.

Future Outlook

The document is a beneficial ownership report and does not contain forward-looking statements or guidance regarding the company's future performance or strategic outlook.

Industry Context

This filing is a routine disclosure of beneficial ownership by an individual, likely an insider, in a biotechnology company. Such filings provide transparency regarding significant individual holdings but do not typically offer insights into broader industry trends or competitive landscapes.

Stakeholder Impact

• Shareholders: The filing provides transparency regarding a significant insider stake, which can be viewed positively as it aligns management's interests with shareholder returns.

Key Dates

Keywords

MAIA BIOTECHNOLOGY, Sergei M. Gryaznov, Beneficial Ownership, Schedule 13G, Common Stock, Stock Options, Insider Ownership, SEC Filing, Biotechnology